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William Young  
BMS 599 
Dr. Michael Kimber  
Exosomes and Their Complex Role in Pathogenesis 
Introduction  
The intriguing nature of exosomes dates to the year 1983 when they were first reported 
(Harding et al., 1983).  It was at this moment that a breakthrough had occurred, and an entirely 
new field of microbiology was opened.  Our understanding of exosomes has gone from 
considering them merely waste buckets to recognizing them as key components of cellular 
communication and even therapeutic agents. Thousands of papers have been published regarding 
exosomes, a journal was created that bore the name, Journal of Extracellular Vesicles, and 
various societies were founded solely for exosomes.   While it is widely accepted that exosomes 
are vital players in many significant functions of normal cells, along with diseased cells; the 
contribution that exosomes have on cellular communication has not always been clear and seems 
to take on an ever-evolving role that is hard to quantify or define.  This role may be expanded in 
the near future to therapeutic treatment for a wide array of diseases.  To fully appreciate what is 
currently understood on exosomes, and what their future holds, a background on exosomes is 
required. 
Biogenesis  
 Exosomes arise from late endosomes during the endosomal pathway.  These late 
endosomes have predominately two fates, fuse with lysosomes where the contents of the vesicle 
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can be degraded, or to be shuttled to the plasma membrane and be released as exosomes.  These 
multivesicular endosomes that are not fused with lysosomes begin the biogenesis of exosomes.  
This process is the first step of exosomal secretion and involves many different proteins.  
Portions of the late endosome undergo inward budding to form ILV’s or intraluminal vesicles.  
This process is carried out by the ESCRT complexes.  ESCRT-0 is comprised of the essential 
protein Hrs (Hessvik et al., 2017).  This complex is responsible for identifying and sequestering 
ubiquitinated proteins.  ESCRT-I is comprised of the essential proteins TSG101 and STAM1 
(Hessvik et al., 2017). ESCRT-I is primarily responsible for the budding and sorting of cargo in 
the vesicles.  Several studies have been done to shown that a lack of ESCRT-0 and ESCRT-I 
complexes greatly reduces production of exosomes.  ESCRT-I and ESCRT-II recruit ESCRT-III.  
The ESCRT-III complex and associated proteins CHMP4C, VPS4B, and VTA1 have been 
shown to play a role in vesicle scission and potentially inhibit the secretion of exosomes 
(Hessvik et al., 2017).  Another protein associated with the ESCRT-III complex, ALIX, changed 
the protein composition of the exosome, signifying that it plays a role in the cargo loading of the 
exosomes and doesn’t inhibit the secretion like the other proteins associated with the ESCRT-III 
complex (Hessvik et al., 2017).  Another group of proteins responsible for the formation and 
secretion of exosomes are syndecans, which are membrane proteins.  These proteins have been 
shown to bind ALIX and their binding seems to impact the formation of intraluminal vesicles.    
Upon arrival at the plasma membrane, the multivesicular bodies are fused with the 
membrane via Rab GTPases.  These Rab proteins are essential to the fusion and ultimately 
secretion of the exosomes.  Rab11 mutants show inhibition of exosomal release in drosophila but 
do not inhibit exosome release in HeLa cells (Hessvik et al., 2017).  However, a knockdown of 
the Rab35 protein did show a reduce in the exosome release of the proteolipid protein in 
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oligodendroglial cell line Oli-neu but not in drosophila (Hessvik et al., 2017).  This protein is 
thought to help coordinate the docking of the multivesicular bodies to the plasma membrane.  It 
is these ESCRT complexes and Rab proteins that will be touched on later due to their role during 
viral infections.      
Lipids also greatly impact the formation and transportation of these vesicles.  Ceramide, a 
waxy lipid molecule, seems to be of great importance to the exosomal release.  When 
sphingomyelinase 2, which is an enzyme that produces ceramide from sphingomyelin, was 
inhibited, there was a decrease of exosomal secretion of the proteolipid protein (Hessvik et al., 
2017).  Another enzyme that plays a role is phospholipase D2 which is an effector of ADP 
ribosylation factor 6 which regulates ILV formation.      
 
Raposo, G. & Stoorvogel, W. et al., 2013 
Figure 1: Shows a clear distinction between exosomes and other types of extra cellular vesicles.  As can be 
seen, the microvesicles bud directly from the plasma membrane whereas exosomes bud into multivesicular 
endosomes which then fuse with the plasma membrane and then exosomes are released.    
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Exosomal markers     
Exosomes are small, 30-150 nm, vesicles that are released from late endosomes.  This is 
in contrast with many other types of Extracellular Vesicles, EV’s, that bud directly from the 
plasma membrane and are released into the extra cellular environment. To distinguish these 
vesicles from each other, markers are generally used.  Exosomes usually contain certain cellular 
contents that can act as markers in identifying exosomes.  In this sense, exosomes have become 
the ‘fingerprints” of individual cells and can help to identify what type of cell an exosome came 
from as well as the health of the cell.  Markers change due to viral vs bacterial infections and 
also differ when a cell has become cancerous.  These usual markers include mRNA, miRNA, 
proteins and lipids.  All of which differ by cell type and are used for cellular communication.  In 
a study done by Dr. Joanna Kowal, western blots were done on several different sizes pellets to 
gauge the different proteins in exosomes versus differing EVs.  The most common proteins 
found were CD9, CD63, and CD81 (Kowal et al., 2016).    The proteins Alix, HSP70, and 
HSP90 are also very often found in most exosomes and can be used as markers (Kowal et al., 
2016).  These proteins are vital for studies that rely on and require exosomes as their primary 
focus of study.  In many of the reports discussed, it is these markers that were keyed on and once 
identified, the vesicles could then be defined as exosomes.     
Cancerous Exosomes  
 The role of exosomes in cancer development has garnered more scrutiny in the last 
decade as more information shows their vital role in cellular communication.  There are several 
ways that exosomes that are derived from cancerous cells can contribute to the progression of 
cancer.   
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The first way that it is able to do this is by furthering the oncogenic nature of already 
existing tumor cells.  These cancerous cells can horizontally transfer mutant proteins such as 
EGFRvIII (Epidermal growth Factor Receptor Variant 3) via exosomes (Salomon et al., 2015). 
This exchange information results in an increase of survival genes and a decrease of cell cycle 
inhibitors (Salomon et al., 2015).   
The second major way that cancerous exosomes promote growth of the malignant tumor 
is by facilitating a favorable environment for the tumor.  Tumor cells release exosomes that 
promote angiogenesis (Salomon et al., 2015)..  It is this angiogenesis that allows the cancer to 
remain nourished and continue to grow.  Myofibroblasts are also a huge part of the growth of the 
tumor, because they are the originator of many matrix remodeling proteins.  These cancerous 
exosomes are released and function to support myofibroblasts thus playing a major part in aiding 
matrix remodeling proteins.  Mu et al. shows that exosomes can degrade the extra cellular matrix 
by integrated proteases.  This releases growth factors and cytokines within the extra cellular 
matrix producing further anti apoptotic effects while increasing proliferation of invasive cancer 
cells.  Another way that a favorable environment is produced was demonstrated in a paper by Dr. 
Hector Peinado.  It stated that melanoma cancer cells educate bone marrow cells in order to 
promote a favorable microenvironment for the primary tumor.  They do this by using the MET 
receptor, elevating its expression during metastasis.  The MET receptor tyrosine kinase is a 
receptor that promotes mitogenic cellular responses. In this way, the exosomes are essential in 
promoting a protumor environment.  
There are many important correlations between exosomes and tumors that are useful for 
both understanding how exosomes help to spread cancer and potentially provide therapy. First, 
the amount of exosomes present in circulation has a direct correlation with the size of the tumor 
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(Fleming, A. et al).  This could potentially be a novel way to determine the extent to which the 
cancer has spread and if markers can be identified, which tissues are compromised.  Second, 
there is evidence that exosomes play a role in the direct migration of the tumor.  In a study by 
Hood et al., 2011, cancer cells prepare distal tissues for colonization through exosomes.  In the 
study tt was shown that sentinel lymph nodes preferentially take up melanoma exosomes.  Free 
melanoma cells are then recruited to the lymph nodes that have the melanoma exosomes and can 
subsequently be spread to distal tissue.  This whole process is requires the involvement of genes 
that control recruitment, angiogenesis, and extra cellular matric modification.             
Melanoma Signatures  
 One of the more well documented cases of cancerous exosomes was done by Dr. Deyi 
Xiao in the paper “Identifying mRNA, MicroRNA and Protein Profiles of Melanoma Exosomes” 
which shows the profiles of the genes, RNA and protein contents of exosomes derived from 
melanoma cells.  Studies were done with normal epidermal melanocytes cell lines (HEMa-LP 
and NHEM-c cells) and malignant melanoma cell lines (A375 and SK-MEL-28).  Exosomes 
were then isolated from the cell lines via ultrafiltration and ultracentrifugation.  When an 
exosome pellet was finally produced, Nanodrop was used to determine the quantity.  
Transmission Electron Microscopy (TEM), RNA isolation and microarray analysis were then 
performed.  TEM revealed that the vesicles were the correct size, between 50 – 100 nm and a 
western blot showed that CD81 was present in sample but not in cell lysates which confirms the 
vesicles were exosomes.  mRNA genome arrays were conducted on all cell lines to distinguish 
different genes expressed in normal melanocytes versus cells with melanoma.  Of the genes 
differentiated in the A375 cell line, many are implicated in N-glycan biosynthesis which is 
involved in melanoma cell metastasis.     
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The miRNA in exosomes has been shown to be strongly correlated with tumorigenesis 
and metastasis in the paper “Exosomes: proteomic insights and diagnostic potential” among 
many others.  Thus, miRNA’s from the A375 cell line and the HEMa-LP cell line were looked at 
in order to differentiate.  Around 230 miRNA’s were differentially expressed in A375 exosomes 
versus HEMa-LP exosomes.  Many of these different miRNA’s, around 70, were associated with 
cancer. Furthermore, many other of these differentially expressed miRNA’s functioned in 
mechanisms that were closely tied with cancer, including, cell growth and proliferation, cellular 
development, cellular movement and cell death.  Among those miRNA’s that were 
downregulated in the cancerous exosomes, were has-miR-31 and has-miR-185.  These miRNAs 
are directly involved in the regulation of aggressive features of melanoma (Xiao, D. et al. 2012).  
The conclusion that can be inferred from these miRNA findings, is that exosomes that arise from 
melanoma contain many miRNA’s that are of great importance in the growth, metastasis and 
invasiveness of the cancer.  
Protein profiles were produced on the A375 cell line and the HEMa-LP cell line to 
establish specific differences.   The proteins annexin A1, annexin A2, syntenin-1, and 
hyaluronan and proteoglycan link protein 1 (HAPLN1), all have association with metastasis, 
invasiveness and angiogenesis.  Annexin A1 and HAPLN1 were both upregulated in A375 
exosomes while Annexin A2 and syntenin-1 were slightly downregulated.  We can infer from 
these results that Annexin A2 and HAPLIN1 have potentially more important and specific roles 
in the growth of the melanoma.    
After a gene is transcribed into mRNA’s and miRNA’s they can then target various other 
genes that code for functional proteins.  And as we have seen, exosomes from cancerous cells 
have differentiated genes, mRNA’s and miRNA’s and proteins.  So, it is conclusive to 
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acknowledge that in this way, the genes, RNA’s, and proteins that an exosome carries, 
incorporates all the essential messages, needed to continue the growth and metastasis of the 
tumor, to deliver to a none cancerous cell.  The culmination of the work done in this lab was to 
prove just that.  A375 exosomes were incubated with HEMa-LP cells and a migration/invasive 
assay was performed.  It was showed that the percent invasion of these HEMa-LP cells after 
incubation were far greater than the control cells.  This ultimately proves that exosomes from 
melanoma cells are mediators and play a significant role in metastatic growth.   
Viral Exosomes  
 Virus’s often use the host cells endocytic pathway as a means of entry and exit from the 
cell.  This is primarily because the budding of viruses and the endocytic pathway both need 
membrane curving, packaging and budding for release.  There are a number of different virus’s 
that use clathrin-mediated endocytosis and enter the late endosomal pathway, fuse with ILV’s 
and ultimately influence the biogenesis and contents of exosomes.    
Biogenesis  
 A major way that virus’s complete their life cycle and spread, is by hijacking the 
biogenesis of exosomes.  They due this primarily by altering the ESCRT and Rab GTPase 
proteins which are essential in biogenesis of exosomes.  The “Trojan Exosome hypothesis” states 
that HIV-1 uses the exosome biogenesis to package its capsid and uses the exosomes to further 
infection in the absence of viral envelope proteins (Fleming et al. 2014).  Beyond this, the role of 
the ESCRT proteins in the development of the hepatitis virus family is well-studied.   HCV 
(hepatitis c virus) has been shown to us the protein Hrs, part of the ESCRT-0 complex, to initiate 
the multivesicular bodies to uptake the viral capsid (Fleming et al., 2014).  HAV and HEV 
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circulate in the body as membrane enclosed virions and avoid detection from the host immune 
response.  In a recent paper it was suggested that the construction of these membrane enclosed 
virions involves the use of many integral ESCRT proteins (Khan et al., 2017).  HAV requires 
CHMP2a which is part of the ESCRT-III complex, Alix, and VSP4 which is an ESCRT-I, and 
ESCRT-III associated protein (Khan et al., 2017).  While HEV requires CHMP2a, Alix and Hrs 
which is part of the ESCRT-0 complex (Khan et al., 2017).         
 Other than the ESCRT pathways, the Rab GTPases are also utilized by many different 
viruses in order to continue their development.  For example, in a study involving hantavirus-
infected cells, interference with the Rab11 protein decreased virion production tenfold (Khan et 
al., 2017).  This suggests that the hantavirus hijacks the Rab11 pathway and uses it do multiply 
and spread. Another Rab GTPase that is commonly hijacked is the protein Rab27a, that plays an 
important role in the fusion of exosomes with the plasma membrane.  Viruses such as 
cytomegalovirus and HIV have been shown to upregulate the production and levels of Rab27a 
ultimately raising exosomal production (Khan et al., 2017).   
Viral Markers 
 When analyzed, exosomes derived from virally infected cells yield major differences 
from exosomes that arise from uninfected cells.    In a study done with infected B cells from the 
Kaposi’s sarcoma herpes virus (KSHV), and/or the Epstein–Barr Virus (EBV), mass 
spectrometry profiled the various proteins that were present (Fleming et al., 2014).  It was 
determined that there were 345 additional proteins incorporated in the infected cells exosomes 
than in the non-infected exosomes (Fleming et al. 2014).  Different exosomes contained unique 
proteins that affected various bodily pathways.  This insinuates that these hijacked exosomes 
have varying functions that may be complementary.  A few of the pathways that these virus’s 
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affected were metabolism, protein translation and cellular migration.  However, protein content 
was not the only change in the viral exosome cargo. The mRNA, miRNA and small non-protein 
coding RNA cargo of exosomes released by virally infected cells was different to that of 
exosomes released by cells not infected by virus. Specifically, in the Epstein-Barr Virus, the 
virus’ miRNAs paired with the natural miRNAs seem to help modulate the expression of target 
genes in the accepting cell (Fleming et al., 2014).   These exosomes also have two small RNA’s, 
EBER-1 and EBER-2, that are RNA polymerase II/III transcripts (Fleming et al., 2014).    These 
RNA segments are untranslated and are implicated in oncogenesis.  The exosomal biogenesis 
hijacking, combined with the release of viral contents in the exosomal cargo, shows how viruses 
can evade immunity, proliferate and increase infectivity.  
 A different way that virus’s can use exosomes to further their reproduction was shown in 
a study on HIV.  It has been shown that exosomes derived from cells infected by HIV can 
transmit the HIV virus receptors CCR5 and CXCR4, to non-infected cells, furthering the 
infection (Khan et al., 2017).  Separately, viruses such as hepatitis C don’t need receptors, and 
package their entire RNA genome within the exosomes (Khan et al., 2017).  This is very 
beneficial for the virus because it reduces the chances of detection via antibodies    
 In a paper by Ahmed et al., it was shown that exosomes from EBV-infected B cells 
induce apoptosis in recipient cells, while non-infected B cells do not.  In this same study, it was 
shown that the apoptosis was induced in the extrinsic pathway involving Fas-ligand (Fas-L), 
contained in the exosomes.  While a different paper by Khan et al., showed that exosomes from 
lymphoblastoid cell lines contain the same ligand, Fas-L and Major Histocompatibility Complex 
II (MHCII) which induces apoptosis is CD4+ T cells.  These two experiments together illustrate 
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how EBV can multiple and proliferate while suppressing the immune response, by inducing 
apoptosis in non-infected lymphocytes.     
Bacterial Exosomes  
 When compared to cancerous and viral cells releasing exosomes, less is known about 
exosomes that arise from cells infected by a bacterium.  In contrast to much evidence that viral 
exosomes help to spread and benefit the virus, exosomes from cells infected by bacteria have 
been shown to promote inflammation and other immune responses such as B and T cell 
stimulation and macrophage chemotaxis (Fleming et al., 2014).  In other studies, infected 
exosomes effect on cytokines is more convoluted as there is evidence that the exosomes help 
cytokines induce B cell stimulation while also inhibiting T cell response.  However, when 
looking at the effect of Mycobacterium tuberculosis, it has been concluded through a study by 
Singh et al., that exosomes from infected cells contain factors that down regulate immune genes 
such as nitric oxide synthase, PGE2 synthase, and HSP70.  It can be reasonably inferred from 
this mixture of data that the role exosomes play in cellular communication during bacterial 
infections is multifaceted and complex and can differ tremendously according to different 
bacterial infections.    
A study by Dr. Adam Fleming investigated the miRNA content of exosomes arising from 
THP 1 cells infected with either Yersinia pestis or Bacillus anthracis.  It was concluded that the 
relative amounts of host miRNA were different in the infected cells as compared to the 
noninfected cells.  Moreover, the differing type of infection seems to play a role in the exosomal 
packaging specificity.  The figure below shows the changes in the amount of miRNA found in 
exosomes derived from cells infected with Y. Pestis or Bacillus anthracis.  Each column signals 
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an individual exosomal miRNA, the red color denotes an increase in miRNA in exosomes in 
infected cells compared to control cells, while a green color denotes a decrease.    
     
Figure 2: Variances in amount of exosomal miRNA due to differing bacterial infection.   
 Red color signifies miRNA increase in exosomes derived from infected cells   
 relative to the uninfected control, while green color signifies miRNA decrease. 
  
Further studies have been produced to analyze proteomic constituents in exosomes 
arising from bacterially infected cells.  One such study by Oehmcke et al., 2013 profiles the 
proteins in exosomes from cells that have been infected by Streptococcus pyogenes.  The goal of 
this study was to do a proteomic profile of pro coagulant exosomes that result from cells infected 
by S. pyogenes.   Exosomes were isolated and analyzed by mass spectrometry to identify proteins 
that were upregulated when exposed to M1.  M1 is a virulence factor closely associated with S. 
pyogenes.   It is thought that this protein will stimulate coagulation cascade pathways.  The 
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results of the experiment yielded 169 proteins in the exosomes in both the control and the 
stimulated exosomes.  The concentration of specific types of proteins was different however.  
The control group had the following concentrations: 57% of the proteins were cytosolic, 23% 
secreted, 12% membrane-associated, and 8% mitochondrial origin.  While the cells stimulated 
with M1 released exosomes with: 35% of the proteins were cytosolic, 36% secreted, 28% 
membrane-associated, and 1% mitochondrian origin.  Fibrinogen-binding integrin CD18 was 
also upregulated by 42 times and CD11b upregulated 7.8 times. lysozyme and neutrophil 
defensin 1, which are proteins that function as antimicrobials, were upregulated 3.7 and 2.8 times 
respectively.        
   The same paper revealed a study looking at the effects when pro-coagulant exosomes 
were applied to the local site of Streptococcus pyogenes infection in mice.  Three groups of mice 
were infected with Streptococcus pyogenes and were either not treated, treated with control 
exosomes, or treated with pro-coagulant exosomes.  The group treated with pro-coagulant 
exosomes had prolonged survival and significantly reduced mortality rates.  This data further 
shows that these pro-coagulant exosomes are part of the body’s innate defense and are part of an 
early immune response.    
Exosomes in Therapy  
 The information currently being gathered within the scientific community regarding 
exosomes is changing our understanding of disease progression and potentially opening new 
doors and tools to help fight that progression.  Knowing now how widely the contents of 
exosomes can vary.  Having knowledge of the various contents, yielding insight into which cells 
are releasing which exosomes, will allow exosomes to be used as biomarkers for the diagnosis of 
different diseases.  This has already been done in some cancer cases and could be a leap forward 
14 
 
in early detection of malignancies.  A great example of this potential effectiveness was a study 
done on ovarian cancer. 
 Currently, the best biomarker available for detecting ovarian cancer is cancer antigen 125 
(CA-125) (Salomon et al., 2015).   However, there are major problems with CA-125.  It can only 
legally be used in patients that already have been diagnosed with ovarian cancer and it meant to 
be used simply to monitor the disease.  Also, it is only elevated in 50-60% of early stage cancer 
patients (Salomon et al., 2015).  Exosomes on the other hand, have many characteristics that 
make them an ideal diagnostic tool, many of which have already been discussed.  Exosomes are 
released from cancer cells and their cargo represents what cell type they come from and their 
environment.  But exosomes have even more properties that further its potential as diagnostic 
tools.  Exosomes can be collected from a several different biofluids including blood, urine or 
saliva.  Once collected, the exosomes are highly stable, and can be easily separated from other 
common proteins found in the fluid.  A couple proteins that have been identified as markers in 
ovarian cancer are CD24 and EpCAM (Salomon et al., 2015).  Furthermore, when a single 
diagnostic marker is unavailable, exosomes may still help by displaying mutated DNA or RNA 
or oncogenic protein.  
    Biomarkers are an important part of the future for exosomes but are not the whole 
picture.  In 2005 a study was performed by Dr. Michael A. Morse to test the effectiveness of 
exosomes for treatment in non-small cell lung cancer (NSCLC).  The study centers around 
exosomes released from dendritic cells called “dexosomes”.  These dexosomes are thought to 
prime T cells and help eliminate tumors in some rodents.  They do this by containing within 
them MHC class I and II molecules and several tetraspan proteins such as CD63 and CD81.  The 
dexosomes act as a relay system in the immune response in the following way.  After obtaining 
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the antigen, a dendrite will incorporate MHC-antigenic peptide complexes into its dexosomes.  
These dexosomes will then stimulate naïve dendritic cells in the lymph nodes, giving them the 
ability to stimulate CD4+ and CD8+ T cells.  
In the study, 9 patients were selected to receive these dexosomes, that were treated with 
tumor associated antigen MAGE to illicit a T cell response, with either stage IV or III NSCLC.  
The results of the study show a somewhat mixed response.  3 of the 9 patients showed positive 
signs of delayed type hypersensitivity.  Furthermore, the peptide-specific immune response to 
MAGE was analyzed using ELISPOT in 5 of 9 dosed patients with one of these patients showing 
increased T cell precursor levels.  In 2/3 patients who had analyzable specimen, an increase in 
CD4+CD25+ T cells as a percentage of CD4+ T cells was observed following completion of 
dexosome therapy when compared with baseline values.  As an aside, the dexosomes seemed to, 
unexpectedly, increase the natural killer cells activity in half of the patients.  2 of the 9 patients 
had disease progression at the beginning of the treatment.  Both of these patients experienced 
clinical stability for some time before progression resumed.  4 of the 9 patients were stable as 
treatment began.  2 of the 4 remained stable for more than 12 months following treatment.  One 
patient died unexpectedly while the other remained stable for 3 months before progression.  
These results show that treatment with exosomes is a viable option.  That exosomes or 
dexosomes can be manufactured and safely administered to patients in hopes of treating specific 
cancers. 
Conclusion  
 Exosomes are nano sized extracellular vesicles that arise from the late endosomal 
pathway.  They are proving to be integral components of cellular commination and play a part in 
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pathogenesis and the immune systems reaction.  Depending on the type of disease, there are 
many ways forward in the world of exosomes.    
Cancerous exosomes appear to be a mixed bag of proteins and but seem to contain 
identifiable markers.  When looking for a way to exploit exosomes in their role of cancer 
development, the first answer now seems to be to use them in a diagnostic way.  It is to develop 
lists of protein and/or RNA signatures that are identifiable to one specific cancer.  In this way, 
screening for multiple various cancers can be simplified and easily obtained.  Beyonf this, more 
research could be put into using exosomes or “dexosomes” to treat certain cancers.  The initial 
studies seem to show that exosomes role in cancer therapy is possible and may have great 
potential.   
 Going forward, exosomes in viral infections may be a good target for therapy and 
treatment.  Specific proteins, such as Rab27a and Rab11 can be targeted for inhibition, as it has 
been shown that these proteins are vital in exosomal release and this pathway is regularly taken 
advantage of by viruses.  Viruses seem to be the pathogen that most utilized exosomes and its 
pathway through the cell.  In this way, the more we understand about exosomes, the more we 
will know about how viruses manage to spread in such a rapid manner.     
 As far as bacterial infections are concerned, procoagulant exosomes effect on mice 
infected with the bacteria Streptococcus pyogenes, was positive with an increased likelihood of 
survival.  This demonstrates, although more testing needs to be done, that procoagulant 
exosomes should be considered as a future route in treating bacterial infections. In all three 
cases, more research and a better understanding may lead to many therapeutic benefits.       
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Cellular communication is a topic of intense study and interest.  It is a vital step in 
pathogenesis and in the body’s defense and immune response to a pathogen.  Exosomes function 
in this process is starting to become illuminated.  More study needs to be done to better 
understand the implications of exosomes in viral and bacterial infections.  But the information 
already present paints a picture that both benefits the pathogen and stimulates an immune 
response in many cases.  This suggests that exosomes are a microcosm of their tissue and 
environment and can potentially be targeted for diagnosis and possibly treatment.  The job they 
hold in cancer metastasis is similar, but more complicated.  Cancer exosomes seem to be directly 
incorporated into the development and advance of cancers with very little redeeming qualities.  
Though the potential place of exosomes in both diagnosis and therapy for cancers seems to be an 
exciting and promising avenue.      
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